Progress is being made in the fight against lung cancer. A new report from the American Lung Association shows that survival has jumped significantly as the rate of eligible people getting low-dose CT lung cancer screening continues to edge up.
Lung cancer is one of the deadliest cancers, mainly because patients historically have been diagnosed at a late stage, when treatment is less effective.
- That’s begun to change with growing adoption of LDCT screening, and providers that have implemented successful screening programs have seen a stage shift to earlier cancer detection – and thus improved patient survival.
But much work remains to be done. The ALA began tracking the progress against lung cancer in a series of annual reports starting in 2018, and this year’s publication chronicles both the wins and losses. On the positive side…
- The U.S. lung cancer incidence rate is declining, with 229k people diagnosed this year, an 11% improvement over five years.
- The LDCT screening rate for eligible people in 2024 was 24%, compared to 18% previously.
- The national average of people living five years after a lung cancer diagnosis has gone up 13 percentage points since the ALA’s first report (31% vs. 18%).
- 29% of people nationally receive an early diagnosis, with 65% five-year survival.
But the ALA report also reveals negative trends, including…
- Major regional variation in lung cancer incidence, with Utah seeing the lowest incidence rates per 100k population and Kentucky the highest (25 and 84).
- The highest survival rates are in Massachusetts, and the lowest in Alabama (41% and 24%).
- Massachusetts also had the highest screening rate, and South Dakota the lowest (39% and 14%).
- Survival rates varied by race, with much lower survival for Black and Native Americans compared to Whites (26%, 18%, and 31%, respectively).
- 43% of people got a late-stage diagnosis, at which point survival is only 12%.
The Takeaway
The new ALA report shows that lung cancer remains the leading cause of cancer mortality in the U.S. But progress is being made, and survival is sure to rise as researchers share strategies for getting more eligible people to attend LDCT screening.
